Lung Cancer Staging Medical Slides
Generate publication-quality lung cancer staging lecture slides in 30 seconds. AI-powered content structured for clinical education.
Generate Lung Cancer Staging DeckWhy teach Lung Cancer Staging?
Lung cancer remains the leading cause of cancer death worldwide with 1.8 million deaths annually. The 8th edition TNM staging system (2017) introduced new T-category size cutoffs and reclassified several nodal and metastatic scenarios. Teaching lung cancer staging requires integration of imaging interpretation, tissue sampling techniques, molecular profiling, and PD-L1 assessment to guide therapy selection.
What AI generates for Lung Cancer Staging
Enter “Lung Cancer Staging” and SlideCraft generates a complete lecture deck with slides like these.
Veja em ação
Digite qualquer tema médico e veja a IA gerar um slide de apresentação em segundos. Sem necessidade de cadastro.
3 previews gratuitos por hora · Sem necessidade de conta
Digite um tema e clique em Gerar para ver seu slide com IA
Lung Cancer Staging Presentation FAQ
How should the 8th edition TNM changes be highlighted in staging slides?
Present the new T-category size cutoffs: T1a (≤1 cm), T1b (>1-2 cm), T1c (>2-3 cm), T2a (>3-4 cm), T2b (>4-5 cm), T3 (>5-7 cm), T4 (>7 cm). Emphasize the key changes from the 7th edition — size became the dominant T-descriptor, diaphragm invasion was reclassified to T4, and mediastinal pleural invasion was removed. Include the new M1a/M1b/M1c subcategories based on metastatic burden.
What molecular testing panel should be presented for NSCLC?
Present the NCCN-recommended panel: EGFR mutations (exon 19 del, L858R — erlotinib/osimertinib), ALK rearrangements (alectinib first-line per ALEX trial), ROS1 fusions (crizotinib/entrectinib), BRAF V600E (dabrafenib-trametinib), KRAS G12C (sotorasib/adagrasib), MET exon 14 skipping, RET fusions, NTRK fusions, and HER2 mutations. Emphasize reflexive broad panel NGS testing for all non-squamous NSCLC and never-smoker squamous histology.
How should PD-L1 and immunotherapy selection be covered?
Present PD-L1 TPS (tumor proportion score) cutoffs: ≥50% (pembrolizumab monotherapy per KEYNOTE-024), 1-49% (combination chemo-immunotherapy per KEYNOTE-189/407), <1% (chemo-immunotherapy, consider nivolumab-ipilimumab per CheckMate 227). Emphasize testing with 22C3 pharmDx assay, timing before first-line therapy, and that PD-L1 is an imperfect biomarker — TMB may add predictive value.
Preços simples, sem surpresas
Comece grátis hoje. Assine quando seu departamento precisar de mais.
Gratuito
Experimente o SlideCraft sem compromisso
- 2 apresentações por mês
- Slides com IA + notas do apresentador
- Visualizar e apresentar (sem exportar)
- Armazenamento na nuvem por 7 dias
- Slide Checker & Outline Generator
Pro
Para clínicos que dão aula toda semana
- 10 apresentações/mês + $2.50/extra
- Modo Crítico com IA (análise 5 eixos)
- Documento para apresentação (PDF)
- Exportar PDF, PPTX, SCORM e imagem
- Armazenamento permanente na nuvem
Expert
Para médicos acadêmicos que publicam e apresentam
- 25 apresentações/mês + $2.00/extra
- Verificação de fontes PubMed
- Pipeline artigo-para-apresentação
- Citações automáticas (Vancouver)
- Tudo do plano Pro